Fla. Biotech Co.'s Misleading IPO Hurt Investors, Suit Says

By Nathan Hale (September 14, 2021, 7:49 PM EDT) -- A biotechnology company cofounded by one of South Florida's most prominent real estate developers has been hit with a proposed securities class action claiming the company made false and misleading statements about a key product in the months leading up to and following its February initial stock offering.

Shareholder Jerald Vargas Malespin claims that Miami-based Longeveron Inc., which says on its website that it is developing cellular therapies to address certain age-related and life-threatening conditions, negligently prepared its stock offering documents and made materially misleading statements or omissions regarding its lead investigational product, Lomecel-B, as well as its business operations and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!